Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes
Author(s) -
Kennedy R. Lees,
Jonathan Emberson,
Lisa Blackwell,
Erich Bluhmki,
Stephen M. Davis,
Geoffrey A. Donnan,
James C. Grotta,
Markku Kaste,
Rüdiger von Kummer,
Maarten G. Lansberg,
Richard I. Lindley,
Patrick D. Lyden,
Gordon Murray,
Peter Sandercock,
Danilo Toni,
Ḱazunori Toyoda,
Joanna M. Wardlaw,
William Whiteley,
Colin Baigent,
Werner Hacke,
George Howard,
John R. Marler,
Heather Halls,
Lisa Holland,
Clare Mathews,
Samantha Smith,
Kate Wilson,
Masatoshi Koga,
Gregory W. Albers,
Thomas Brott,
Geoffrey Cohen,
JeanMarc Olivot,
Mark Parsons,
Barbara C. Tilley,
Nils Wahlgren,
Gregory J. del Zoppo
Publication year - 2016
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.116.013644
Subject(s) - medicine , stroke (engine) , acute stroke , thrombolysis , fibrinolytic agent , cardiology , physical medicine and rehabilitation , intensive care medicine , physical therapy , tissue plasminogen activator , myocardial infarction , mechanical engineering , engineering
Thrombolytic therapy with intravenous alteplase within 4.5 hours of ischemic stroke onset increases the overall likelihood of an excellent outcome (no, or nondisabling, symptoms). Any improvement in functional outcome distribution has value, and herein we provide an assessment of the effect of alteplase on the distribution of the functional level by treatment delay, age, and stroke severity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom